Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MLYCD | O95822 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9900386 | 0.91 | ALDH1A1 (0.49) | SMN1; SMN2L3MBTL1MLYCDNAAAHTT | |
| SCHEMBL9900587 | 0.84 | CA12 (0.41) | HDAC1ALDH1A1HPGDMEN1MAPT | |
| SCHEMBL28326194 | 0.80 | L3MBTL1 (0.73) | SMN1; SMN2L3MBTL1MLYCDNAAATSHR | |
| SCHEMBL12615099 | 0.75 | HDAC8 (0.48) | SMN1; SMN2TSHRHTTHDAC2CA2 | |
| SCHEMBL12989186 | 0.75 | SMN1; SMN2 (0.66) | SMN1; SMN2L3MBTL1MLYCDNAAATSHR | |
| SCHEMBL24386079 | 0.74 | L3MBTL1 (0.71) | SMN1; SMN2L3MBTL1MLYCDNAAAHDAC3 | |
| SCHEMBL13494653 | 0.74 | L3MBTL1 (0.61) | SMN1; SMN2L3MBTL1MLYCDNAAATSHR | |
| SCHEMBL4318844 | 0.74 | SMN1; SMN2 (0.64) | SMN1; SMN2L3MBTL1MLYCDNAAATSHR | |
| SCHEMBL178367 | 0.74 | L3MBTL1 (0.87) | SMN1; SMN2L3MBTL1MLYCDNAAATSHR | |
| SCHEMBL22919705 | 0.74 | L3MBTL1 (0.65) | SMN1; SMN2L3MBTL1MLYCDNAAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | claimed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | claimed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | claimed |
| EP-2702063-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-03-05 | — | — | EP | claimed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | claimed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | claimed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | claimed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | claimed |
| US-9187486-B2 | Bicyclic pyridazine compounds as Pim inhibitors | AMGEN INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9090593-B2 | Bicyclic compounds as Pim inhibitors | AMGEN INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2796456-A1 | Bicyclic compounds as Pim inhibitors | Amgen Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | AMGEN INC. | 2014-08-07 | — | — | US | disclosed |
| EP-2702063-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2649065-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012148775-A1 | BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012078777-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031360-A1 | BICYCLIC COMPOUNDS AS PIM INHIBITORS | PIM1, PIM2, PIM3 | SMN1; SMN2 4085/4885L3MBTL1 1581/4885MLYCD 800/4885 |
| US-20140221344-A1 | Bicyclic Pyridazine Compounds as PIM Inhibitors | PIM1, PIM2, PIM3 | SMN1; SMN2 3773/4885L3MBTL1 2307/4885MLYCD 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.